Verrica Pharmaceuticals IncNASDAQ:VRCANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.4200
- TODAY'S CHANGE (%)-0.1800 (-11.2500%)
- Bid / Lots1.4100/ 4
- Ask / Lots1.4700/ 90
- Open / Previous Close1.6000 / 1.6000
- Day Range
- 52 Week Range
- Volume266,496
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VRCA |
|---|---|---|
| 09:32 ET | 2850 | 1.6194 |
| 09:36 ET | 442 | 1.57 |
| 09:38 ET | 100 | 1.57 |
| 09:39 ET | 10178 | 1.555 |
| 09:41 ET | 200 | 1.56 |
| 09:43 ET | 11675 | 1.55 |
| 09:48 ET | 100 | 1.54 |
| 09:54 ET | 4800 | 1.5251 |
| 09:56 ET | 1947 | 1.54 |
| 09:57 ET | 516 | 1.53 |
| 09:59 ET | 310 | 1.5205 |
| 10:01 ET | 29654 | 1.5005 |
| 10:03 ET | 1685 | 1.51 |
| 10:06 ET | 8918 | 1.5095 |
| 10:08 ET | 7114 | 1.5099 |
| 10:10 ET | 1300 | 1.51 |
| 10:12 ET | 3771 | 1.5268 |
| 10:14 ET | 1269 | 1.5205 |
| 10:15 ET | 100 | 1.52 |
| 10:17 ET | 1200 | 1.52 |
| 10:19 ET | 400 | 1.52 |
| 10:21 ET | 372 | 1.5095 |
| 10:24 ET | 4751 | 1.52 |
| 10:26 ET | 1201 | 1.505 |
| 10:32 ET | 1000 | 1.51 |
| 10:35 ET | 100 | 1.5 |
| 10:37 ET | 100 | 1.5 |
| 10:39 ET | 4325 | 1.485 |
| 10:42 ET | 1063 | 1.4905 |
| 10:44 ET | 841 | 1.4895 |
| 10:46 ET | 100 | 1.49 |
| 10:48 ET | 200 | 1.4845 |
| 10:51 ET | 464 | 1.4808 |
| 10:53 ET | 1994 | 1.48 |
| 10:55 ET | 100 | 1.475 |
| 10:57 ET | 498 | 1.47 |
| 11:00 ET | 12609 | 1.49 |
| 11:09 ET | 877 | 1.4795 |
| 11:13 ET | 300 | 1.4798 |
| 11:15 ET | 2314 | 1.4628 |
| 11:20 ET | 1000 | 1.468 |
| 11:22 ET | 663 | 1.46 |
| 11:24 ET | 800 | 1.47 |
| 11:26 ET | 1500 | 1.475 |
| 11:31 ET | 1325 | 1.465 |
| 11:33 ET | 867 | 1.465 |
| 11:36 ET | 400 | 1.465 |
| 11:38 ET | 342 | 1.46 |
| 11:45 ET | 1653 | 1.475 |
| 11:47 ET | 664 | 1.4795 |
| 11:54 ET | 200 | 1.47 |
| 11:58 ET | 100 | 1.47 |
| 12:00 ET | 128 | 1.47 |
| 12:07 ET | 129 | 1.47 |
| 12:09 ET | 100 | 1.4798 |
| 12:14 ET | 650 | 1.48 |
| 12:23 ET | 300 | 1.475 |
| 12:27 ET | 200 | 1.47 |
| 12:30 ET | 100 | 1.47 |
| 12:32 ET | 229 | 1.47 |
| 12:36 ET | 8500 | 1.47 |
| 12:38 ET | 477 | 1.46 |
| 12:41 ET | 4007 | 1.4503 |
| 12:48 ET | 200 | 1.44 |
| 12:56 ET | 550 | 1.4498 |
| 12:59 ET | 100 | 1.445 |
| 01:01 ET | 500 | 1.4495 |
| 01:03 ET | 1828 | 1.445 |
| 01:06 ET | 1600 | 1.44 |
| 01:10 ET | 854 | 1.4405 |
| 01:12 ET | 3909 | 1.4401 |
| 01:14 ET | 500 | 1.445 |
| 01:17 ET | 200 | 1.4431 |
| 01:26 ET | 200 | 1.448791 |
| 01:28 ET | 3023 | 1.4407 |
| 01:30 ET | 164 | 1.44 |
| 01:32 ET | 1346 | 1.4405 |
| 01:33 ET | 757 | 1.4407 |
| 01:44 ET | 100 | 1.44 |
| 01:48 ET | 725 | 1.445 |
| 01:57 ET | 100 | 1.4495 |
| 02:04 ET | 100 | 1.44 |
| 02:06 ET | 1320 | 1.4495 |
| 02:09 ET | 242 | 1.4405 |
| 02:11 ET | 143 | 1.4495 |
| 02:13 ET | 209 | 1.445 |
| 02:15 ET | 654 | 1.448707 |
| 02:20 ET | 100 | 1.44 |
| 02:29 ET | 600 | 1.4476 |
| 02:36 ET | 808 | 1.45 |
| 02:38 ET | 3279 | 1.4499 |
| 02:40 ET | 250 | 1.4489 |
| 02:44 ET | 1098 | 1.4405 |
| 02:47 ET | 1000 | 1.445 |
| 02:51 ET | 100 | 1.44 |
| 02:56 ET | 2035 | 1.4495 |
| 03:03 ET | 700 | 1.4495 |
| 03:05 ET | 290 | 1.445 |
| 03:07 ET | 400 | 1.445 |
| 03:09 ET | 100 | 1.445 |
| 03:12 ET | 11488 | 1.455 |
| 03:14 ET | 300 | 1.4501 |
| 03:18 ET | 1814 | 1.455 |
| 03:20 ET | 200 | 1.45 |
| 03:21 ET | 100 | 1.45 |
| 03:23 ET | 100 | 1.45 |
| 03:27 ET | 100 | 1.45 |
| 03:32 ET | 360 | 1.46 |
| 03:36 ET | 683 | 1.4597 |
| 03:39 ET | 1027 | 1.4545 |
| 03:41 ET | 100 | 1.45 |
| 03:43 ET | 203 | 1.4505 |
| 03:45 ET | 16524 | 1.435 |
| 03:48 ET | 1110 | 1.43 |
| 03:50 ET | 3093 | 1.43 |
| 03:52 ET | 2059 | 1.42 |
| 03:54 ET | 600 | 1.42 |
| 03:56 ET | 700 | 1.42 |
| 03:57 ET | 1728 | 1.42 |
| 03:59 ET | 27422 | 1.42 |
Yesterday
Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements, from 10:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
10:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
Oct 24, 2024
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference, from 7:01AM ET on Thursday Oct 24, 2024 by Dow Jones
7:01AM ET on Thursday Oct 24, 2024 by Dow Jones
Oct 21, 2024
DJ Verrica Pharmaceuticals Is Maintained at Buy by TD Cowen, from 1:20PM ET on Monday Oct 21, 2024 by Dow Jones
1:20PM ET on Monday Oct 21, 2024 by Dow Jones
Oct 11, 2024
Oct 8, 2024
Grabar Law Office Continues to Investigate Claims on Behalf of Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA), from 9:41AM ET on Tuesday Oct 08, 2024 by Dow Jones
9:41AM ET on Tuesday Oct 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Verrica Pharmaceuticals Inc | 68.3M | -0.8x | --- |
I-Mab | 89.8M | 0.0x | --- |
Cellectar Biosciences Inc | 73.5M | -0.6x | --- |
United-Guardian Inc | 62.5M | 18.8x | -9.92% |
Zhong Yuan Bio-Technology Holdings Ltd | 88.2M | 391.4x | --- |
Spectral Medical Inc | 122.1M | -9.2x | --- |
Company Information
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Contact Information
- Headquarters
- 10 N High St Ste 200WEST CHESTER, PA, United States 19380-3014
- Phone
- 484-453-3300
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Ted White
- General Counsel, Company Secretary, Chief Legal Office
- Christopher Hayes
- Chief Medical Officer
- Gary Goldenberg
- Director
- Sean Stalfort
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $68.3M |
|---|---|
Revenue (TTM) | $13.9M |
Shares Outstanding | 42.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-1.88 |
Book Value | $0.47 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 4.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -581.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
